Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT OTCMKTS:EMIS NASDAQ:VERU NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/AEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AVERUVeru$0.60+3.0%$0.57$0.45▼$1.42$85.49M-0.751.93 million shs1.56 million shsXENEXenon Pharmaceuticals$32.21-2.3%$31.88$26.74▼$46.00$2.53B1.1638,352 shs595,207 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+1.89%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%VERUVeru+2.97%+0.08%-10.71%+10.65%-31.84%XENEXenon Pharmaceuticals-2.33%-7.19%-0.15%+2.58%-18.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AVERUVeru2.8951 of 5 stars3.54.00.00.03.31.70.0XENEXenon Pharmaceuticals3.4574 of 5 stars4.54.00.00.01.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/AEMISEmisphere Technologies 0.00N/AN/AN/AVERUVeru 3.00Buy$4.00566.11% UpsideXENEXenon Pharmaceuticals 3.00Buy$54.8270.19% UpsideCurrent Analyst Ratings BreakdownLatest CALT, EMIS, XENE, and VERU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025XENEXenon PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.005/13/2025XENEXenon PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.005/13/2025XENEXenon PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$53.00 ➝ $53.005/13/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/13/2025XENEXenon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $55.005/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/5/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/17/2025XENEXenon PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $52.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AVERUVeru$16.89M5.21N/AN/A$0.22 per share2.73XENEXenon Pharmaceuticals$9.43M262.09N/AN/A$9.90 per share3.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/AEMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AVERUVeru-$37.80M-$0.24N/AN/AN/AN/A-128.51%-76.51%8/6/2025 (Estimated)XENEXenon Pharmaceuticals-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)Latest CALT, EMIS, XENE, and VERU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million5/8/2025Q2 2025VERUVeru-$0.06-$0.05+$0.01-$0.05$0.73 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59EMISEmisphere TechnologiesN/AN/AN/AVERUVeruN/A3.803.80XENEXenon PharmaceuticalsN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%EMISEmisphere TechnologiesN/AVERUVeru47.16%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%EMISEmisphere Technologies72.90%VERUVeru15.20%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableVERUVeru230146.58 million124.30 millionOptionableXENEXenon Pharmaceuticals21076.73 million72.50 millionOptionableCALT, EMIS, XENE, and VERU HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from BrokeragesJuly 10 at 2:57 AM | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by BrokeragesJuly 10 at 2:55 AM | marketbeat.comTraders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)July 10 at 2:20 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Cross Below 200 Day Moving Average - Here's WhyJuly 5, 2025 | marketbeat.comXenon Appoints CEO Ian Mortimer as Interim CFOJuly 3, 2025 | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - NasdaqJune 29, 2025 | nasdaq.comXenon Pharmaceuticals Joins Russell 3000® and 2000® IndexesJune 27, 2025 | tipranks.comXenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual ReconstitutionJune 27, 2025 | quiverquant.comQXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | financialpost.comFXenon Joins the Russell 3000® and Russell 2000® IndexesJune 27, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2025 | globenewswire.comXenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)June 26, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?June 25, 2025 | marketbeat.comXenon Announces Appointment of Darren Cline as Chief Commercial OfficerJune 24, 2025 | globenewswire.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's WhyJune 16, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsJune 15, 2025 | marketbeat.comTraders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)June 12, 2025 | marketbeat.comXenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?June 11, 2025 | zacks.comXenon to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCALT, EMIS, XENE, and VERU Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 07/11/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Emisphere Technologies OTCMKTS:EMIS$7.81 0.00 (0.00%) As of 12/9/2020Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Veru NASDAQ:VERU$0.60 +0.02 (+2.97%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.75%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Xenon Pharmaceuticals NASDAQ:XENE$32.21 -0.77 (-2.33%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$32.17 -0.04 (-0.11%) As of 07/11/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
